Supplementary tables: Real-world association of HER2/ERBB2 concordance with trastuzumab clinical benefit in advanced esophagogastric cancer.docx

Supplementary table 1a: Versions of genomic sequencing
and genes included (FoundationOne Version 1)
Supplementary
table 1b: Versions of genomic sequencing and genes included (FoundationOne
Version 2)
Supplementary
table 1c: FoundationOne CDx (Version 3)
Supplemental
table 2: Detailed patient selection criteria
Supplemental
table 3: Patients with an unknown or indeterminate HER2 test results who met
all other study inclusion criteria
Supplemental
table 4: First line anti-HER2 therapy regimens in HER2+ patients stratified
by ERBB2 amplification status
Supplemental
table 5: Demographics and clinical characteristics of patients with HER2+
tumors who received first-line trastuzumab therapy
Supplemental
table 6: Concurrent genomic alterations
Supplemental
table 7: Distribution of ISH results for patients classified by IHC status
(with positive ISH confirmation) (n = 59), by ERBB2 Amp
Supplemental
table 8: Adjusted clinical outcomes for 1L trastuzumab in patients whose
tumors were clinically HER2+, adjusting for IHC status (n=142)
Supplemental
table 9: Adjusted clinical outcomes for 1L trastuzumab in patients by
adjusting for <i>KRAS</i> status (n=142)

补充表1a：纳入的基因组测序版本及基因（FoundationOne 版本1）
补充表1b：纳入的基因组测序版本及基因（FoundationOne 版本2）
补充表1c：FoundationOne CDx（伴随诊断，Companion Diagnostic）（版本3）
补充表2：详细的患者入组标准
补充表3：满足研究其余所有入组标准，但人表皮生长因子受体2（HER2, Human Epidermal Growth Factor Receptor 2）检测结果为未知或不确定的患者
补充表4：按ERBB2扩增状态分层的HER2阳性患者的一线抗HER2治疗方案
补充表5：接受一线曲妥珠单抗治疗的HER2阳性肿瘤患者的人口学特征及临床特征
补充表6：共存基因组变异
补充表7：按免疫组化（IHC, Immunohistochemistry）状态分类的患者的原位杂交（ISH, In Situ Hybridization）结果分布（经ISH阳性确认，n=59），按ERBB2扩增情况分层
补充表8：针对免疫组化（IHC）状态进行校正后，临床判定为HER2阳性的肿瘤患者接受一线曲妥珠单抗治疗的校正临床结局（n=142）
补充表9：针对Kirsten大鼠肉瘤病毒癌基因同源物（KRAS）状态进行校正后，患者接受一线曲妥珠单抗治疗的校正临床结局（n=142）